Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines

Sakaguchi, Masahiro; Miyazawa, Hiroshi; Inouye, Sakae

doi:10.1034/j.1398-9995.2001.056006536.x

Cited by 51 publications

(16 citation statements)

References 21 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A few cases of hypersensitivity such as allergic oedema and even anaphylaxis have been observed after the application of the vaccine, but most probably due to gelatine components [10,24,26]. There are many different recommendations for vaccination schedules [23].…”

Section: Prevention Of Japanese Encephalitismentioning

confidence: 99%

Japanese encephalitis and vaccines: past and future prospects

Paulke‐Korinek

Kollaritsch

2008

Wien Klin Wochenschr

View full text Add to dashboard Cite

The Japanese encephalitis virus is the main cause of encephalitis in Asia. The vectors are mosquitoes. Every year 30,000 to 50,000 cases and 10,000 deaths from Japanese encephalitis are reported, and estimates go up to 100,000 cases. No effective antiviral therapy exists to treat this flavivirus infection. For prophylaxis vaccines are available. In Asia numerous vaccines are used regionally. The production of the only vaccine that was internationally licensed, JE-VAX, was ceased in 2005. Therefore a shortage of Japanese encephalitis vaccines might occur before new generation vaccines based on cell cultures will be available. An inactivated Vero cell-derived vaccine based on the Beijing-1 strain is developed in Japan by Biken and Kaketsuken. Another promising vaccine candidate is the inactivated whole-virus vaccine IC-51 (Strain SA14-14-2) by the Austrian company Intercell. The third interesting vaccine candidate being in the late stages of clinical trials is the genetically engineered, chimeric and live-attenuated vaccine ChimeriVaxtrade mark-JE by the UK/USA-based company Acambis. The new vaccines in the pipeline show promising results and market licensures are expected in the near future. Showing excellent tolerability, these vaccines will not only be used in the population living in endemic areas where the risk of infection is extremely high, but also for travellers and military personnel.

show abstract

Section: Prevention Of Japanese Encephalitismentioning

confidence: 99%

Japanese encephalitis and vaccines: past and future prospects

Paulke‐Korinek

Kollaritsch

2008

Wien Klin Wochenschr

View full text Add to dashboard Cite

show abstract

“…[97][98][99] Las formas orales, como las cápsulas, son toleradas generalmente. 100,101 Las PLV presentes en la triple bacteriana acelular y Sabín 102,103 pueden generar reacciones, aunque la mayoría las tolera.…”

Section: Vacuna Y Medicamentosunclassified

Alergia alimentaria en pediatría: recomendaciones para su diagnóstico y tratamiento. Texto completo

Alergia¹

2018

Arch Argent Pediatr

View full text Add to dashboard Cite

“…Cependant, les injections de vaccins peuvent induire des ré-actions allergiques du type immédiat, comme des réactions anaphylactiques et des urticaires et/ou angioedèmes aux vaccins contenant des anatoxines [12,41,53], de l'ovalbumine [6,24], de la gélatine [32,49,50,52], et des antigènes pneumococciques [42]. Les vaccins contenant du dextran (BCG ® ) peuvent induire des réactions anaphylactoïdes dépendant des IgG [25,48].…”

Section: -104unclassified

“…Certaines sont locales, comme les eczémas induits par l'hydroxyde d'aluminium [14,26], le mercurothiolate [46] et le formaldéhyde [47], les réactions à type de phénomène d'Arthus [15,30], et les abcès récurrents stériles [13] induits par les anatoxines. Les autres sont généralisées, comme certaines urticaires, certains angioedèmes et certaines éruptions non urticariennes liées aux injections de vaccins contenant de la gélatine [32,50,57].…”

Section: -104unclassified